Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 7:22 p.m.

    📋 IMMUNOVANT, INC. (IMVT) - Financial Results

    Filing Date: 2022-08-05

    Accepted: 2022-08-05 07:07:36

    Event Type: Financial Results

    Event Details:

    Immunovant Inc (IMVT) Reports Q3 2022 Financial Results Immunovant Inc (IMVT) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: $31 million
      • expected in the second half of calendar year 2024
      • expected in the first half of calendar year 2025
      • targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com. Forward-Looking StatementsThis press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Operating Expenses Net Loss -40.37K -30.47K $-9.90K -32.50%
    Operating Expenses Net Loss Per Share -0.35 -0.31 $-0.04 -12.90%

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Immunovant Inc
    • CIK: 0001764013
    • Ticker Symbol: IMVT
    • Period End Date: 2022-08-05
    • Document Type: 8-K

Search

News categories